ACADIA Pharmaceuticals (ACAD) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ACADIA Pharmaceuticals (ACAD) has outperformed Viking Therapeutics (VKTX) over the past year, losing 8.1% versus a loss of 14.3%. Over five years, VKTX leads with a +361.4% price change compared with +11.8% for ACAD. Viking Therapeutics is the larger company by market cap ($3.53 billion vs $3.37 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | VKTX |
|---|---|---|
| Share price | $19.58 | $27.73 |
| Market cap | $3.37B | $3.53B |
| 1-day change | -0.36% | -2.84% |
| YTD return | -26.69% | -21.18% |
| 1-year return | -8.12% | -14.33% |
| 5-year return | +11.82% | +361.40% |
| P/E ratio (TTM) | 8.78 | — |
| Forward P/E | 22.04 | — |
| EPS (TTM) | $2.23 | $-4.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.07B | $0 |
| Revenue growth (YoY) | +11.87% | — |
| Net income (latest FY) | $391.00M | $-359.64M |
| Gross margin | 91.69% | — |
| Operating margin | 9.78% | — |
| Net margin | 36.49% | — |
| 52-week high | $30.96 | $43.15 |
| 52-week low | $19.32 | $25.77 |
| Distance from 52-week high | -36.76% | -35.74% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +64.25% | +241.54% |
| Average volume | 1.85M | 4.13M |
| Shares outstanding | 172.31M | 127.17M |
| Employees | 796 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
ACAD vs VKTX FAQ
Which is bigger, ACADIA Pharmaceuticals or Viking Therapeutics?
Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.53B compared with $3.37B for ACADIA Pharmaceuticals (ACAD).
Which stock has performed better over the past year, ACAD or VKTX?
ACAD returned -8.12% over the past 12 months, compared with -14.33% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.